NeuroOne (NMTC) insider sale — 30,000 shares disposed, ownership now 231,238

Rhea-AI Filing Summary

NeuroOne Medical Technologies (NMTC) insider sale disclosed on Form 4. The reporting person, Mark Christianson, identified as a director and Business Development Director, sold 30,000 shares of common stock on 09/05/2025 at a weighted average price of $0.7401 per share, with individual sale prices ranging from $0.7400 to $0.7518. After the reported transactions, the filing shows 231,238 shares beneficially owned. The Form 4 was signed by a power of attorney on 09/09/2025. No derivative securities are reported on this form.

Positive

• Transaction disclosed with specific details including date, number of shares, and weighted average price
• Reporting person identified as both a director and Business Development Director, clarifying role and potential access to material information
• No derivative securities reported, simplifying the change to straight common-stock ownership

Negative

• Insider sold 30,000 shares (disposition reported), reducing direct beneficial ownership
• Beneficial ownership decreased to 231,238 shares following the reported sale

Insights

Corporate Governance Expert

TL;DR: Insider sale disclosed; ownership decreased to 231,238 shares; disclosure appears complete for the reported non-derivative transaction.

The Form 4 documents a straightforward open-market sale by an officer/director. Key items are clearly reported: transaction date (09/05/2025), number of shares sold (30,000), weighted average price ($0.7401) and resulting beneficial ownership (231,238 shares). The filing includes an explanation that the reported price is a weighted average across multiple trades and offers to provide per-trade details on request. No options, warrants or other derivative instruments are listed, so the submission focuses solely on common-stock changes.

Securities Analyst

TL;DR: This is a disclosed insider sale with clear pricing and post-transaction ownership; no additional material events are reported.

The transaction information is specific: 30,000 shares sold at prices between $0.7400 and $0.7518, producing a reported weighted average of $0.7401. The form indicates the shares were disposed (code S) and lists no derivative activity. The signature block shows filing via power of attorney dated 09/09/2025. From a reporting standpoint, the entry provides the essential data an investor or compliance reviewer would need to track insider ownership changes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Christianson Mark

(Last) (First) (Middle)

7599 ANAGRAM DR.

(Street)

EDEN PRAIRIE MN 55344

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NEUROONE MEDICAL TECHNOLOGIES Corp [ NMTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Business Development Director

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/05/2025		S		30,000	D	$0.7401(1)	231,238	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $0.7400 to $0.7518 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price.

	Emily Johns, by Power of Attorney	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did NMTC report on this Form 4?

The filing reports that Mark Christianson sold 30,000 shares of NeuroOne common stock on 09/05/2025.

At what price were the NMTC shares sold by the insider?

The shares were sold at prices ranging from $0.7400 to $0.7518 per share with a reported weighted average price of $0.7401.

How many NMTC shares does the reporting person own after the sale?

After the reported transaction the filing shows the reporting person beneficially owns 231,238 shares.

Who filed and signed the Form 4 for this NMTC transaction?

The Form 4 was signed on behalf of the reporting person by Emily Johns under power of attorney on 09/09/2025.

Did the Form 4 report any derivative securities for NMTC?

No. Table II for derivative securities contains no reported transactions; only common-stock (non-derivative) disposition is listed.